Stocks · Healthcare · Drug Manufacturers - Specialty & Generic
Journey Medical Corporation DERM
$6.61 -1.64% Close, Oct 2, 2026 · NASDAQ · Market cap $181.9M
Next earnings report: Nov 11, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The diluted share count rose 18.0% in a year.
- Operating margin widened to -4.4% from -12.2% a year earlier.
- Revenue over the last four quarters was $68.2M, up 20.9% from a year earlier, accelerating from 15.0% a quarter earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 32%
- Revenue growth, 3-year CAGRBottom 14%
- Revenue growth accelerationTop 16%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 38%
- Gross marginBottom 47%
- Operating marginTop 47%
- Accruals (lower is better)Bottom 14%
- Net debt / EBITDA (lower is better)Top 35%
- Interest coverTop 47%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 39%
- Free-cash-flow yieldTop 49%
- EBITDA / enterprise valueTop 35%
- Sales / enterprise valueTop 33%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 40%
- 6-month returnTop 29%
- 1-year return vs S&P 500Bottom 36%
- Distance from 52-week highTop 48%
- Trend checklist (0–4)Bottom 38%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 30%
- Consecutive EPS beatsBottom 49%
- Share of analysts rating BuyTop 10%
- Upside to consensus price targetTop 44%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 48%
- Maximum drawdown, 3 yearsTop 40%
- Beta vs S&P 500 (lower is better)Top 9%
- Net debt / EBITDA (lower is better)Top 35%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 15.0% | 20.9% | ↑ |
| Gross margin | 65.6% | 62.2% | ↓ |
| Operating margin | -12.2% | -4.4% | ↑ |
| FCF margin | -4.8% | -11.0% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 20.9% | 15.0% | ↑ | Top 32% |
| Gross margin | 62.2% | 65.6% | ↓ | Bottom 47% |
| Operating margin | -4.4% | -12.2% | ↑ | Top 47% |
| Net margin | -9.0% | -15.5% | ↑ | — |
| Free-cash-flow margin | -11.0% | -4.8% | ↓ | — |
| Return on invested capital | -5.2% | — | Top 38% | |
| Revenue growth, 3-year CAGR | -5.7% | — | Bottom 14% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 1.4%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 8.9%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +110.8 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- -0.06×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -0.8×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -4.12%
- Shareholder yield
- -4.12%
- Share count change, 1 year
- +18.0%
- Share count change, 3-year CAGR
- +15.2%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 12, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 1
- Beats in the last 8 reports
- 5 of 8
- Average EPS surprise, last 4
- +15.5%
- Average 2-day reaction, last 8
- -0.0%
- Positive 20 days after report
- 4 of 8
Analysts
- Consensus price target
- $11.75
- Target vs current price
- +77.8%
- Analysts with a rating
- 3
- Share rating Buy or Strong Buy
- 100%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 12, 2026 | +55.6% | +1.7% | +5.4% | +17.9% | — |
| May 13, 2026 | -14.3% | +3.6% | +22.8% | +21.2% | +28.3% |
| Mar 25, 2026 | +33.3% | -1.2% | -32.1% | -27.1% | -10.0% |
| Nov 12, 2025 | -12.5% | +0.3% | -12.2% | -14.9% | -11.2% |
| Aug 12, 2025 | -128.6% | +8.5% | -11.1% | -5.3% | +14.4% |
| May 14, 2025 | +25.0% | -5.5% | +8.9% | +9.3% | +19.8% |
| Mar 26, 2025 | +136.4% | -5.2% | -7.9% | +15.4% | +0.5% |
| Nov 12, 2024 | +29.4% | -2.3% | -9.5% | -2.5% | -6.1% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 12, 2026 | -$0.01 | -$0.02 | +55.6% | $18.5M |
| May 13, 2026 | -$0.08 | -$0.07 | -14.3% | $16.0M |
| Mar 25, 2026 | -$0.04 | -$0.06 | +33.3% | $16.1M |
| Nov 12, 2025 | -$0.09 | -$0.08 | -12.5% | $17.6M |
| Aug 12, 2025 | -$0.16 | -$0.07 | -128.6% | $15.0M |
| May 14, 2025 | -$0.18 | -$0.24 | +25.0% | $13.1M |
| Mar 26, 2025 | $0.08 | -$0.22 | +136.4% | $13.6M |
| Nov 12, 2024 | -$0.12 | -$0.17 | +29.4% | $14.6M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / EBITDA | 98.3× | — | — | Top 35% |
| EV / Sales | 2.67× | — | — | Top 33% |
| Free-cash-flow yield | -4.12% | — | — | Top 49% |
| Earnings yield | -3.42% | — | — | Top 39% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- +0.5%
- 200-day average slope (20 days)
- -1.1%
- Distance from 50-day average
- -4.8%
- Distance from 200-day average
- -3.7%
- RSI (14)
- 43.7
- Relative volume
- 0.70×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 54.4%
- Volatility vs own 5-year history
- 6th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.31
- Correlation with S&P 500
- 0.08
- Current drawdown from 1-year high
- -28.6%
- Maximum drawdown, 3 years
- -63.3%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Nov 12, 2021 | May 18, 2023 | -89.1% | 379 days | Not yet recovered |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $181.9M
- EPS, diluted (TTM)
- -$0.23
- Revenue (TTM)
- $68.2M
- 52-week range
- $4.31 – $9.56
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $63.1M | $73.7M | $79.2M | $56.1M | $61.9M |
| Gross profit | $31.1M | $42.9M | $52.5M | $35.3M | $36.7M |
| Operating income | -$34.9M | -$27.5M | -$2.1M | -$13.7M | -$8.2M |
| Net income | -$44.0M | -$29.6M | -$3.9M | -$14.7M | -$11.4M |
| EPS (diluted) | -$2.54 | -$1.69 | -$0.21 | -$0.72 | -$0.47 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.6M | $13.6M | $13.1M | $15.0M | $17.6M | $16.1M | $16.0M | $18.5M |
| Net income | -$2.4M | $1.5M | -$4.1M | -$3.8M | -$2.3M | -$1.2M | -$2.2M | -$312,000 |
| EPS (diluted) | -$0.12 | $0.07 | -$0.18 | -$0.16 | -$0.09 | -$0.05 | -$0.08 | -$0.01 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$2.2M | -$13.5M | $5.2M | -$9.1M | -$12.4M |
| Capital expenditure | -$10.0M | -$20.0M | -$5.0M | -$15.0M | $0 |
| Free cash flow | -$12.2M | -$33.5M | $240,000 | -$24.1M | -$12.4M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $32.5M | $142,000 | $4.6M | $416,000 | $567,000 |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $25.6M
- Total assets
- $98.4M
- Total liabilities
- $66.2M
- Total debt
- $25.5M
- Net debt
- -$102,000
- Shareholders’ equity
- $32.1M
As of Jun 30, 2026 (filed Aug 12, 2026).
Short interest
- Shares sold short
- 2,927,514
- Days to cover
- 22.52
- Change vs previous report
- -1.1%
FINRA short interest, settlement date Sep 15, 2026.